Anika Therapeutics, Inc.

NasdaqGS:ANIK Stock Report

Market Cap: US$207.8m

Anika Therapeutics Future Growth

Future criteria checks 0/6

Anika Therapeutics is forecast to grow earnings and revenue by 53.6% and 2.2% per annum respectively. EPS is expected to grow by 51.5% per annum. Return on equity is forecast to be 6.5% in 3 years.

Key information

53.6%

Earnings growth rate

51.5%

EPS growth rate

Biotechs earnings growth24.2%
Revenue growth rate2.2%
Future return on equity6.5%
Analyst coverage

Low

Last updated29 Apr 2025

Recent future growth updates

Recent updates

Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet

Dec 19
Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Jan 30
Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Aug 03
Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity

Mar 11

Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Jun 25
Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Mar 16
How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

Feb 09
Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

Jan 13
An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Dec 18
If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Earnings and Revenue Growth Forecasts

NasdaqGS:ANIK - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027129-46N/A1
12/31/2026122-114243
12/31/2025113-92123
12/31/2024120-9-35N/A
9/30/2024164-98-17N/A
6/30/2024167-7419N/A
3/31/2024169-77-42N/A
12/31/2023121-3-7-2N/A
9/30/2023163-25-11-5N/A
6/30/2023162-22-16-9N/A
3/31/2023157-22-53N/A
12/31/20221142-34N/A
9/30/2022152-1628N/A
6/30/2022152-1128N/A
3/31/2022150-239N/A
12/31/2021148438N/A
9/30/2021145-627N/A
6/30/2021137-13710N/A
3/31/2021129-27810N/A
12/31/2020130-241113N/A
9/30/2020128-42224N/A
6/30/2020126112628N/A
3/31/2020125282730N/A
12/31/2019115273437N/A
9/30/2019112313134N/A
6/30/2019109293135N/A
3/31/2019109303134N/A
12/31/2018106193035N/A
9/30/201810819N/A32N/A
6/30/201810818N/A33N/A
3/31/201811120N/A35N/A
12/31/201711332N/A41N/A
9/30/201711332N/A40N/A
6/30/201711134N/A39N/A
3/31/201710431N/A32N/A
12/31/201610333N/A24N/A
9/30/201610636N/A34N/A
6/30/201610335N/A31N/A
3/31/201610034N/A43N/A
12/31/20159331N/A40N/A
9/30/20158528N/A39N/A
6/30/20158425N/A37N/A
3/31/20158727N/A30N/A
12/31/201410638N/A40N/A
9/30/201410437N/A33N/A
6/30/20149936N/A33N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANIK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANIK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANIK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANIK's revenue (2.2% per year) is forecast to grow slower than the US market (8.4% per year).

High Growth Revenue: ANIK's revenue (2.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ANIK's Return on Equity is forecast to be low in 3 years time (6.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/06 12:49
End of Day Share Price 2025/05/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Anika Therapeutics, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Anderson SchockB. Riley Securities, Inc.
Mark LandyNorthland Capital Markets